Getting to BIDMC    Contact BIDMC    617-667-7000

Events Calendar    News    CAREERS @ BIDMC

ABOUT BIDMC CENTERS & DEPARTMENTS PATIENT & VISITOR INFORMATION YOUR HEALTH QUALITY & SAFETY MEDICAL EDUCATION RESEARCH GIVE TO BIDMC
 

BIDMC Research Investigator / Faculty Information

Rebecca A Miksad MD,MPH

Instructor

Hematology and Oncology

Faculty Appointment:

Hematology and Oncology

   

Contact Information:

 
Title:   Instructor
Office:   FD-224
Phone:   617-667-9159
Fax:   617-975-8030
Email:   rmiksad@bidmc.harvard.edu
Address:   Beth Israel Deaconess Medical Center
 330 Brookline Ave; FD-224
 Boston, MA 02215

Advanced Degree And Training Info:

Year

Institution

Area or Rank

2001  Cornell University  MD Honors in Research
2001  Memorial Sloan Kettering  Intern/Resident
2001  New York Hospital  Intern/Resident
2004  Beth Israel Deaconess Medical Center  Oncology Fellow
2006  Harvard School of Public Health  Master in Public Health

Research Team Listing

No team members listed

Areas of Interest:

Cancer & Hematologic

Epidemiology / Health Outcomes Patient Oriented / Translational  

Major Research Theme:

Dr. Miksad's research goals are to improve oncology treatment decision making through better characterization of cancer patient outcomes, improved accuracy of clinical endpoints, assessment of the economic implications of cancer therapy and application of decision analysis tools.

Select Major Publications:    List of Publications via PubMed database at NIH NLM

Miksad R, Zietemann V, Gothe R, Schwarzer R, Conrads-Frank A, Schnell-Inderst P, Stollenwerk B, Plieschnegger P, Esteban E and Siebert U. Evaluation of Progression-Free Survival as a Surrogate Endpoint in Advanced Breast Cancer. International Journal of Technology Assessment in Health Care. In Press 2008.
Mühlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad R, Siebert U. The cost-effectiveness of primarily HPV-based cervical cancer screening in settings with currently established Pap screening – A systematic review commissioned by the German Federal Ministry of Health International Journal of Technology Assessment in Health Care. International Journal of Technology Assessment in Health Care. 2008 Spring; 24(2):184-192.
Miksad R, Schnipper L, Goldstein M. Does a statistically significant survival benefit for erlotinib plus gemcitabine in advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol. 2007 Oct; 25(28):4506-7.

External Recognition:

Young Investigator Award, American Society of Clinical Oncology, 2007–2008
Timely Special Opportunity Award, Dana-Farber/Harvard Cancer Center, 2007–2008
Program in Cancer Outcomes Research Training, Dana-Farber/Harvard Cancer Center, Research Fellow 2006-2008
Clinical Research Award, Eastern Cooperative Oncology Group Young Investigator Symposium, 2007
Lee Lusted Prize, Society for Medical Decision Making, 2007
Dr. George Altman Oncology Fellow, Beth Israel Deaconess Medical Center, Harvard University, 2006
Head Teaching Fellow, Harvard School of Public Health, 2007: Decision Analysis in Clinical Research (Milton Weinstein, PhD)
Health Policy Research Poster Symposium Prize, Massachusetts Medical Society, 2006

Major Collaborative Activities:

Institute for Technology Assessment, MGH, Senior Scientis
http://www.mgh-ita.org

Investigator's Web Site:

             

Harvard Catalyst Site:

   
 

Copyright 2009 Beth Israel Deaconess Medical Center | Contact Research Webmaster

IP Address: 38.107.191.87   |  Web Server: research.bidmc.harvard.edu   |  Database Server: Colorado\SQL17   |  App Path: /research/ResearchPIInfo.ASP   |  Version:

Browser: CCBot/1.0 (+http://www.commoncrawl.org/bot.html)
SecurityGroup: